shutterstock-193503416-web
Brues / Shutterstock.com
5 August 2014Americas

Akorn settles with FTC to allow VersaPharm merger

US-based injections maker Akorn has agreed to sell its rights to develop, manufacture and market generic tuberculosis injection rifampin to Watson Laboratories to settle charges by the US Federal Trade Commission (FTC) that its proposed acquisition of pharmaceutical company VersaPharm was likely to be anticompetitive.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 April 2026   The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.
Americas
29 April 2026   The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.
Americas
28 April 2026   Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug